Press Release

Progress reported in oncology drug discovery programs

Redwood City, CA – November 13, 2018 – REVOLUTION Medicines, Inc. today announced presentations describing scientific research progress across multiple oncology drug discovery programs.

“In 2018 we’ve made significant progress in both cancer biology and drug discovery toward our goal of translating frontier oncology targets on behalf of cancer patients,” said Mark A. Goldsmith, M.D., Ph.D., president and chief executive officer of REVOLUTION Medicines. “This preclinical work spans multiple elusive cancer targets including SHP2, mTORC1/4EBP1 and oncogenic forms of mutant KRAS.  The discoveries provide the mechanistic foundations for our development strategies in the clinic based on monotherapy directed against molecularly-defined tumors, enhancement of anti-tumor immune responses, and therapeutic drug combinations.”

Third Quarter 2018
 

• Efficacy of SHP2 phosphatase inhibition in cancers with nucleotide-cycling oncogenic RAS, NF1 loss and RAS-GTP-dependent oncogenic BRAF at the FASEB Phosphatase Meeting, poster presented by Franzi Haderk, Ph.D. (UC San Francisco) on July 15, 2018
• Allosteric inhibition of SHP2 variants containing cancer-associated activating mutations at the FASEB Phosphatase Meeting, poster presented by Pete Wildes, Ph.D. (REVOLUTION Medicines) on July 15, 2018
• Functional characterization of SHP2-mediated RAS-MAPK pathway inhibition in cancer cells bearing oncogenic mutations dependent upon nucleotide cycling of RAS at the FASEB Phosphatase Meeting, poster presented by Chris Schultze, Ph.D., Ph.D. (REVOLUTION Medicines) on July 15, 2018
• Efficacy of SHP2 phosphatase inhibition in cancers with nucleotide-cycling oncogenic RAS, NF1 loss and RAS-GTP-dependent oncogenic BRAF at the Salk Meeting on Post-Translational Regulation of Cell Signaling, talk presented by Trever Bivona, M.D., Ph.D. (UC San Francisco) on August 1, 2018
• Combination strategies to enhance the efficacy of SHP2 inhibition at CSHL Mechanisms and Models of Cancer, talk presented by Mallika Singh, Ph.D. (REVOLUTION Medicines) on August 15, 2018
• Efficacy of SHP2 phosphatase inhibition in cancers with nucleotide-cycling oncogenic RAS, NF1 loss and RAS-GTP-dependent oncogenic BRAF at ASBMB Frontiers in RAS Biology, poster presented by Franzi Haderk, Ph.D. (UC San Francisco) on September 14, 2018
• Efficacy of SHP2 phosphatase inhibition in cancers with nucleotide-cycling oncogenic RAS, NF1 loss and RAS-GTP-dependent oncogenic BRAF at ASBMB Frontiers in RAS Biology, talk presented by Trever Bivona, M.D., Ph.D. (UC San Francisco) on September 14, 2018 

Fourth Quarter 2018
 

• SHP2 inhibition in tumors driven by nucleotide cycling oncogenic KRAS and RAS-GTP-independent downstream mutations in the RAS MAPK pathway at Nextgen Genomics, Biology, Bioinformatics and Technology, talk presented by Mallika Singh, Ph.D. (REVOLUTION Medicines) on October 2, 2018
• Allosteric inhibition of SHP2 induces anti-tumor immunity in PD-1-sensitive tumors through modulation of both innate and adaptive mechanisms at 4th CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference, poster presented by Elsa Quintana, Ph.D. (REVOLUTION Medicines) on October 3, 2018
• RMC-4550: An allosteric inhibitor optimized for in vivo studies of SHP2 at CRL Oncology Symposium, talk presented by Elena Koltun, Ph.D. (REVOLUTION Medicines) on October 29, 2018
• Development of inhibitors of the activated form of KRASG12C at 30th EORTC-NCI-AACR Symposium, poster to be presented by Roy Pollock, Ph.D. (Warp Drive Bio, a subsidiary of REVOLUTION Medicines) on November 13-16, 2018
• 4EBP1 reactivation by potent and selective bi-steric inhibitors of mTORC1 at AACR Targeting PIRK/mTOR Signaling, talk to be presented by Nidhi Tibrewal, Ph.D. (REVOLUTION Medicines) on December 1, 2018
• Strategies to target the mTORC1/eIF4F axis in B cell leukemia and lymphoma at AACR Targeting PI3K/mTOR Signaling, talk to be presented by David Fruman, Ph.D. (UC Irvine) on December 2, 2018
• Biophysical and biochemical characterization of KRASG12C inhibition through the SMART platform at AACR Targeting RAS-Driven Cancers, poster to be presented by Earl May, Ph.D. (Warp Drive Bio, a subsidiary of REVOLUTION Medicines) on December 9-12, 2018
• Development of inhibitors of the activated form of KRASG12C at AACR Targeting RAS-Driven Cancers, poster to be presented by Michelle Stewart, Ph.D. (Warp Drive Bio, a subsidiary of REVOLUTION Medicines) on December 9-12, 2018